Celgene's Abraxane meets primary endpoints in pancreatic cancer study

13 November 2012

In what was some good news on the pancreatic cancer scene, the European subsidiary of US biotech firm Celgene Corp (Nasdaq: CELG) says that its Phase III study of Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in treatment-naive patients with advanced pancreatic cancer met its primary endpoint of overall survival.

The stock rose 6% to $75.57 in after-hours trading last Friday when the results were released, and which came ahead of disappointing news for Clavis Pharma’s pancreatic cancer drug candidate CP-4126 (The Pharma Letter November 12). The stock rose to $77.84 in morning trading on Monday. Based on the results of the MPACT study, Celgene plans to submit dossiers for registration in the USA, Europe and other markets.

In the study, Abraxane, already approved and marketed for the treatment of breast and lung cancer, when used in combination with gemcitabine demonstrated a statistically significant improvement in overall survival compared to patients receiving gemcitabine alone.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK